Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

760
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
760
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

358
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
358
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment.

JCO precision oncology·2026
Same author

Aberrant p53 overexpression in benign colon biopsies may predict dysplasia risk in patients with primary sclerosing cholangitis and inflammatory bowel disease.

Histopathology·2026
Same author

Pelvic chemoradiation with high-dose-rate brachytherapy boost for synchronous prostate and rectal cancers: A rare case series and treatment framework.

Brachytherapy·2026
Same author

Aberrant p53 immunohistochemical staining is uncommon in serrated epithelial change, regardless of association with dysplasia.

Histopathology·2026
Same author

Practical therapeutic options for postoperative chylothorax.

Journal of cardiothoracic surgery·2026
Same author

AGA Clinical Practice Update on Management of Gastric Polyps: Expert Review.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same journal

ASO Author Reflections: The Hidden Cost of Gastric Preservation During Cytoreductive Surgery for Pseudomyxoma Peritonei: Understanding the Functional Consequences of Extensive Perigastric Cytoreduction.

Annals of surgical oncology·2026
Same journal

Survival of Squamous Cell Carcinoma Versus Adenocarcinoma in Resected Stage I-III Non-small Cell Lung Cancer.

Annals of surgical oncology·2026
Same journal

ASO Visual Abstract: Quality, Reliability, and Viewer Engagement of YouTube Videos on Esophageal Cancer: A Cross-Sectional Study.

Annals of surgical oncology·2026
Same journal

ASO Visual Abstract: Implementing Paradigm-Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma Patients.

Annals of surgical oncology·2026
Same journal

Trends in Breast and Axillary Operations in Young Patients with Operable Breast Cancer from the National Cancer Database (NCDB): De-escalation of Axillary Surgery and Increased Use of Radiation.

Annals of surgical oncology·2026
Same journal

The Impact of Tumor Size on Therapeutic Decision-Making for Upper Tract Urothelial Carcinoma: A Large-Scale Population Analysis.

Annals of surgical oncology·2026
See all related articles

Related Experiment Video

Updated: Jan 12, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

Long-term Oncologic Outcomes Following Pathologic Complete Response for Esophageal Cancer.

Andrew J Sinnamon1, Samir H Saeed2, Allan A Lima Pereira2

  • 1Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA. Andrew.Sinnamon@moffitt.org.

Annals of Surgical Oncology
|November 5, 2025
PubMed
Summary
This summary is machine-generated.

Pathologic complete response (pCR) after neoadjuvant chemoradiotherapy improves survival for esophageal cancer patients, but recurrence is still common. A new risk score helps predict outcomes for patients with pCR, guiding further treatment decisions.

More Related Videos

Surgical Treatment of an Endolymphatic Sac Tumor
04:34

Surgical Treatment of an Endolymphatic Sac Tumor

Published on: May 26, 2023

1.4K
An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function
09:40

An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function

Published on: April 17, 2020

14.8K

Related Experiment Videos

Last Updated: Jan 12, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K
Surgical Treatment of an Endolymphatic Sac Tumor
04:34

Surgical Treatment of an Endolymphatic Sac Tumor

Published on: May 26, 2023

1.4K
An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function
09:40

An Ivor Lewis Esophagectomy Designed to Minimize Anastomotic Complications and Optimize Conduit Function

Published on: April 17, 2020

14.8K

Area of Science:

  • Oncology
  • Gastroenterology
  • Clinical Research

Background:

  • Neoadjuvant chemoradiation is a standard treatment for locally advanced esophageal cancer.
  • Pathologic complete response (pCR) rates differ significantly between adenocarcinoma (AC) and squamous cell carcinoma (SCC) histologies.
  • Long-term outcomes following pCR are not well understood, necessitating further research.

Purpose of the Study:

  • To evaluate the impact of pCR on long-term survival after neoadjuvant chemoradiation and esophagectomy for esophageal cancer.
  • To identify predictors of recurrence and develop a risk score for patients achieving pCR.

Main Methods:

  • Analysis of 830 patients with locally advanced esophageal AC or SCC treated with neoadjuvant chemoradiation and resection.
  • Assessment of recurrence-free survival (RFS) and overall survival (OS) using Kaplan-Meier and Cox models.
  • Development and external validation of a recurrence risk score using the National Cancer Data Base.

Main Results:

  • 37.1% of patients achieved pCR, with higher rates in SCC (58.0%) compared to AC (34.2%).
  • pCR was independently associated with improved OS (5-year OS: 56.2% vs. 35.0%) and RFS.
  • A validated risk score predicted OS post-pCR, with median OS of 7.8 years for low-risk scores (0-3) versus 5.7 years for high-risk scores (4-5).

Conclusions:

  • pCR after neoadjuvant chemoradiotherapy is a significant predictor of survival in esophageal cancer.
  • Recurrence remains a concern even after achieving pCR, particularly in AC histology.
  • Further research into adjuvant therapies for high-risk pCR patients is warranted to improve outcomes.